DCK, deoxycytidine kinase, 1633

N. diseases: 102; N. variants: 6
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0023418
Disease: leukemia
leukemia 		0.030 GeneticVariation disease BEFREE Resistance to 1,25-dihydroxyvitamin D3 of a deoxycytidine kinase-deficient variant of human leukemia HL60 cells. 1426045 1992
CUI: C1332977
Disease: Childhood Leukemia
Childhood Leukemia 		0.030 GeneticVariation disease BEFREE Resistance to 1,25-dihydroxyvitamin D3 of a deoxycytidine kinase-deficient variant of human leukemia HL60 cells. 1426045 1992
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.100 AlteredExpression group BEFREE Approximately 3 days after the end of the 5-Aza-C infusion, the HDara-C regimen was given again with the idea that the induced DNA hypomethylation in the leukemic cells may have increased the dCk activity and that a reversal of the tumor drug resistance to ara-C could have occurred. 2473850 1989
CUI: C0023449
Disease: Acute lymphocytic leukemia
Acute lymphocytic leukemia 		0.030 Biomarker disease BEFREE Reexpression of dCk could increase the cellular ara-CTP concentrations and the sensitivity to ara-C. A total of 17 pediatric patients with refractory acute lymphocytic leukemia (ALL) received a continuous infusion of 5-Aza-C at 150 mg/m2 daily for 5 days after not responding to (13/17) or relapsing from (4/17) an HDara-C regimen (3 g/m2 over 3 h, every 12 h, x 8 doses). 2473850 1989
CUI: C0024302
Disease: Reticulosarcoma
Reticulosarcoma 		0.010 Biomarker disease BEFREE Characterization of an adenosine deaminase-deficient human histiocytic lymphoma cell line (DHL-9) and selection of mutants deficient in adenosir kinase and deoxycytidine kinase. 6303563 1983
CUI: C0079744
Disease: Diffuse Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma 		0.010 Biomarker disease BEFREE Characterization of an adenosine deaminase-deficient human histiocytic lymphoma cell line (DHL-9) and selection of mutants deficient in adenosir kinase and deoxycytidine kinase. 6303563 1983
CUI: C0334663
Disease: Histiocytic sarcoma
Histiocytic sarcoma 		0.010 Biomarker disease BEFREE Characterization of an adenosine deaminase-deficient human histiocytic lymphoma cell line (DHL-9) and selection of mutants deficient in adenosir kinase and deoxycytidine kinase. 6303563 1983
CUI: C0023467
Disease: Leukemia, Myelocytic, Acute
Leukemia, Myelocytic, Acute 		0.100 GeneticVariation disease BEFREE We conclude that structural alteration of the coding region of the dCK gene represents one possible mechanism for ara-C resistance in vivo, but, considering the frequency of this event, other mechanisms may play a more important role for clinical resistance to ara-C in patients with AML. 7514246 1994
CUI: C0023465
Disease: Acute monocytic leukemia
Acute monocytic leukemia 		0.030 GeneticVariation disease BEFREE We conclude that structural alteration of the coding region of the dCK gene represents one possible mechanism for ara-C resistance in vivo, but, considering the frequency of this event, other mechanisms may play a more important role for clinical resistance to ara-C in patients with AML. 7514246 1994
CUI: C0677936
Disease: Refractory cancer
Refractory cancer 		0.010 GeneticVariation phenotype BEFREE We conclude that structural alteration of the coding region of the dCK gene represents one possible mechanism for ara-C resistance in vivo, but, considering the frequency of this event, other mechanisms may play a more important role for clinical resistance to ara-C in patients with AML. 7514246 1994
CUI: C4528668
Disease: Acute myeloid leukaemia refractory
Acute myeloid leukaemia refractory 		0.010 GeneticVariation disease BEFREE In order to define the relevance of this mechanism in vivo, we analyzed the dCK gene in 16 adult patients with relapsed/refractory acute myeloid leukemia (AML) and clinical resistance to standard-dose and/or high-dose ara-C. Southern blot analysis using genomic DNA from peripheral blood or bone marrow samples containing > or = 70% leukemic blasts and agarose gel electrophoresis of cDNA obtained by RT-PCR did not reveal gross rearrangements of the dCK gene. 7514246 1994
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms 		0.050 GeneticVariation group BEFREE These data suggest that viral vector transduction of the dCK gene followed by treatment with ara-C represents a new chemosensitization strategy for cancer gene therapy. 8616717 1996
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.040 GeneticVariation group BEFREE These data suggest that viral vector transduction of the dCK gene followed by treatment with ara-C represents a new chemosensitization strategy for cancer gene therapy. 8616717 1996
CUI: C0017638
Disease: Glioma
Glioma 		0.010 Biomarker disease BEFREE Viral vector transduction of the human deoxycytidine kinase cDNA sensitizes glioma cells to the cytotoxic effects of cytosine arabinoside in vitro and in vivo. 8616717 1996
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.100 Biomarker group BEFREE Retroviral transfer of deoxycytidine kinase into tumor cell lines enhances nucleoside toxicity. 8625309 1996
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms 		0.050 Biomarker group BEFREE Because many tumors have relatively low levels of dCK, it is possible that dCK gene transfer will be a useful adjunct to the treatment of these malignancies. 8625309 1996
CUI: C0019348
Disease: Herpes Simplex Infections
Herpes Simplex Infections 		0.020 AlteredExpression group BEFREE To develop gene therapy for targeting metastatic lung adenocarcinoma, the toxic activity of herpes simplex virus type 1-thymidine kinase, Escherichia coli cytosine deaminase, and human deoxycytidine kinase were investigated in metastatic human lung adenocarcinoma cell lines H1437 and H2122. 8640820 1996
CUI: C0152013
Disease: Adenocarcinoma of lung (disorder)
Adenocarcinoma of lung (disorder) 		0.010 Biomarker disease BEFREE To develop gene therapy for targeting metastatic lung adenocarcinoma, the toxic activity of herpes simplex virus type 1-thymidine kinase, Escherichia coli cytosine deaminase, and human deoxycytidine kinase were investigated in metastatic human lung adenocarcinoma cell lines H1437 and H2122. 8640820 1996
CUI: C0019348
Disease: Herpes Simplex Infections
Herpes Simplex Infections 		0.020 Biomarker group BEFREE Herpes simplex virus thymidine kinase and ganciclovir (HSV-TK/GCV), Escherichia coli cytosine deaminase and 5-fluorocytosine (CD/5FC), E coli nitroreductase and CB1954 (NTR/CB1954), and human deoxycytidine kinase and cytosine arabinoside (dCK/AraC) were employed. 9673364 1998
CUI: C0023467
Disease: Leukemia, Myelocytic, Acute
Leukemia, Myelocytic, Acute 		0.100 Biomarker disease BEFREE The p16 and dCK CpG islands were also unmethylated in the 8 AML specimens. 9808523 1998
CUI: C0376544
Disease: Hematopoietic Neoplasms
Hematopoietic Neoplasms 		0.010 Biomarker group BEFREE In our study, we used sodium bisulfite sequencing to generate high resolution maps of 5-methylcytosine in the CpG islands associated with p15, p16 and dCK in normal human bone marrow (BM), peripheral blood lymphocytes (PBL) and cytosine arabinoside (ara-C)-resistant acute myeloid leukemia (AML) patients, and established human hematopoietic tumor cell lines. 9808523 1998
CUI: C0013080
Disease: Down Syndrome
Down Syndrome 		0.020 AlteredExpression disease BEFREE Transcripts of deoxycytidine kinase were 2.6-fold higher in DS compared with non-DS cells and may be a factor in the enhanced metabolism of ara-C in DS cells. 10438727 1999
CUI: C4521042
Disease: Complete Trisomy 21 Syndrome
Complete Trisomy 21 Syndrome 		0.020 AlteredExpression disease BEFREE Transcripts of deoxycytidine kinase were 2.6-fold higher in DS compared with non-DS cells and may be a factor in the enhanced metabolism of ara-C in DS cells. 10438727 1999
CUI: C0206726
Disease: gliosarcoma
gliosarcoma 		0.010 GeneticVariation disease BEFREE We examined whether susceptibility of mouse colon carcinoma (Colon 26) and rat gliosarcoma (9L) cells to 1-beta-D-arabiofuranosylcytonsine (AraC), a chemotherapeutic agent, can be increased after the tumor cells were transduced with the human dCK gene. 10880764 2000
CUI: C0699790
Disease: Colon Carcinoma
Colon Carcinoma 		0.010 Biomarker disease BEFREE A histological examination revealed infiltration of eosinophils into the dCK gene-transduced but not into parental Colon 26 tumor. 10880764 2000